Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma

Fig. 8

Characterization and therapeutic efficacy of PLGA-PEG(si-LINC00958) NPs in HCC PDX model. a Representative TEM image of PLGA-PEG(si-LINC00958) NPs. b The size distribution profile of PLGA-PEG(si-LINC00958) NPs. c Cellular uptake of NPs into HCCLM3 cells was evaluated by incubating HCCLM3 cells with Courmarin-6 labeled NPs. d HCC PDX model was used to demonstrate the therapeutic efficacy of PLGA-PEG(si-LINC00958) NPs via the tail vein injection. The harvested xenografted are shown. e Tumor weight was compared between PLGA-PEG(si-LINC00958) NPs and PLGA-PEG(siRNA control) NPs. f Tumor volume was compared between PLGA-PEG(si-LINC00958) NPs and PLGA-PEG(siRNA control) NPs. g RT-qPCR was performed to compare the expression level of LINC00958 between PLGA-PEG(si-LINC00958) NPs and PLGA-PEG(siRNA control) NPs. h Western blotting was performed to compare the expression level of LINC00958 between PLGA-PEG(si-LINC00958) NPs and PLGA-PEG(siRNA control) NPs. i Kaplan-Meier curves were plotted to compare the overall survival between the mice injected with PLGA-PEG(si-LINC00958) NPs and those injected with PLGA-PEG(siRNA control) NPs (P = 0.003). j Representative H&E staining of major organs including the liver, kidney, lung, spleen, and heart at the end of the experiment. k Blood ALT levels between the mice injected with PLGA-PEG(si-LINC00958) NPs and those injected with PLGA-PEG(siRNA control) NPs. l Blood AST levels between the mice injected with PLGA-PEG(si-LINC00958) NPs and those injected with PLGA-PEG(siRNA control) NPs. m Blood Cr levels between the mice injected with PLGA-PEG(si-LINC00958) NPs and those injected with PLGA-PEG(siRNA control) NPs. n BUN levels between the mice injected with PLGA-PEG(si-LINC00958) NPs and those injected with PLGA-PEG(siRNA control) NPs. ***P < 0.001

Back to article page